Resveratrol and Alzheimer’s: What...

Resveratrol, a compound found in red wine and grapes, became one of the...

India's Supplement Market to...

India's health supplements market could reach (Dollar) 9.4 billion...

Why Bipolar Episodes Return...

Even with treatment and stability, bipolar episodes can come back. Here’s how...

Mom With Alzheimer’s Remembers...

A heartwarming and emotional moment that shows the true power of love and...
HomeMental healthWellbeing while waiting:...

Wellbeing while waiting: social prescribing for young people awaiting treatment


Over recent years, reports of mental health difficulties among young people have been on the rise, particularly in relation to anxiety and depression (Kupcova et al., 2023). Alongside this, demand for mental health services has increased, but there is a problem. These much-needed services often have long waiting lists, meaning that many individuals are stuck in limbo while experiencing high levels of distress (Han et al., 2026). So what can be done when demand is greater than the services available to meet it? Here, we turn to social prescribing.

Social prescribing is a form of care focused on connecting individuals to non-clinical support services to improve their health and wellbeing. Examples include community-based activities such as cultural events, the arts and physical activity (read more on the rise of social prescribing in Karen’s Mental Elf blog).

Naturally, with the rise in social prescribing, researchers have set out to explore its effectiveness for those experiencing mental health difficulties. However, previous research has highlighted limitations in the available evidence, including small sample sizes and a lack of appropriate comparison groups. Most prominently, evidence on social prescribing in younger populations, such as adolescents, remains limited, leaving a gap in our understanding of its potential benefits (Muhl et al., 2025).

To address this gap, Hayes et al. (2026) investigated the effectiveness of social prescribing for young people. Specifically, they examined whether social prescribing could improve mental health and wellbeing outcomes while young people waited for Child and Adolescent Mental Health Services (CAMHS). They also wanted to understand its feasibility. In a real-world setting, is social prescribing safe and acceptable to young people?

Long CAMHS waiting lists can leave young people without structured support during a period of considerable distress.

Methods

The authors recruited young people aged 11-18 years across 11 CAMHS sites in England. All sites provided specialist outpatient CAMHS and had waiting times of at least three months for evidence-based psychological treatment.

Using a pragmatic, non-randomised stepped-wedge design, the authors compared two groups of young people at three time points (baseline, three months and six months). The comparison group was recruited before a social prescribing pathway was introduced at each CAMHS site and received usual waiting-list care. The intervention group was recruited after implementation and was offered active support while on the waiting list, typically consisting of six sessions with trained Link Workers.

These sessions focused on facilitating community engagement and identifying personal strengths and goals. The specific structure of sessions varied based on each participant’s needs, with support delivered in person, online or by telephone. Young people could also access a personalised budget of up to £40 to help cover costs such as travel, equipment or activity fees.

The authors assessed a range of outcomes, including:

  • Primary outcomes: emotional and behavioural difficulties, anxiety, depression and perceived stress
  • Secondary outcomes: resilience, wellbeing and the acceptability of social prescribing
  • Clinicians and Link Workers also rated the intervention’s acceptability, feasibility and appropriateness

Growth curve modelling was used to examine changes over time, adjusting for potential confounding factors including age, gender, ethnicity, free school meals and socioeconomic deprivation. 

Results

In total, 558 young people were recruited to the study (333 allocated to social prescribing and 225 to usual care). Of these, 449 participants (248 in the social prescribing group) were included in the final effectiveness analysis. The mean age was approximately 14 years, and both groups were broadly demographically similar, although there were some differences in ethnicity and socioeconomic deprivation.

Of the 333 young people allocated to social prescribing, 54 (16.2%) did not receive the intervention. Among those who received social prescribing and had available session data, participants attended an average of five sessions with a Link Worker.

Does social prescribing improve young people’s mental health while waiting?

  • No statistically significant differences were found between groups for perceived stress, anxiety or depressive symptoms.
  • Young people receiving social prescribing showed small improvements in overall emotional and behavioural difficulties over six months, compared with little change in the control group. However, these improvements were primarily driven by changes in behavioural difficulties, rather than emotional symptoms.
  • More specifically, there was some evidence of differences between groups in conduct problems, hyperactivity and peer problems, although not all differences reached conventional levels of statistical significance.
  • Prosocial behaviour also differed significantly between groups over six months. The social prescribing group showed a slight increase, while the control group showed a decrease.

Does social prescribing improve resilience and wellbeing while waiting?

  • Young people receiving social prescribing showed small improvements in resilience over six months, compared with little change in the control group. There was also some evidence of differences between groups in community participation, self-esteem and problem-solving.
  • No comparable group differences were found in community connection, empathy or goals and aspirations.
  • Life satisfaction increased in both the social prescribing and control groups, with no significant difference between them.
  • Sense of worthwhileness and happiness increased within the social prescribing group, but these improvements were not significantly greater than those observed in the control group.

Was social prescribing acceptable, feasible and safe?

  • During the study, 15 adverse events were reported, but none were considered related to social prescribing.
  • Clinicians and Link Workers rated social prescribing highly for acceptability, appropriateness and feasibility.
  • Young people’s views on acceptability were generally neutral to positive, with only 10–14% expressing disagreement.
'Resilience' written out on wooden Scrabble tiles, with a flower in the background
Social prescribing was associated with small improvements in behavioural difficulties and resilience, but not anxiety, depression or perceived stress.

Conclusion

Overall, Hayes et al. (2026) found that youth social prescribing was associated with small improvements in overall difficulties over six months, particularly in conduct difficulties, hyperactivity and peer problems. They also noted improvements in prosocial behaviour and resilience, particularly in community participation, self-esteem and problem-solving. On the other hand, there were no significant between-group differences in symptoms of anxiety, depression or perceived stress.

Social prescribing also received high acceptability and feasibility ratings from practitioners, while young people largely reported neutral to positive views. These findings suggest that social prescribing may offer additional support while young people wait for CAMHS treatment, particularly in relation to behavioural functioning and resilience. However, the observed improvements were modest, and social prescribing should not be considered a replacement for specialist mental health care.

'Waiting waiting waiting waiting' in red and blue neon lights across a black wall
Social prescribing may offer additional support while young people wait for Child and Adolescent Mental Health Services, but it is not a replacement for specialist treatment.

Strengths and limitations

Strengths

Overall, the study makes a meaningful contribution to the limited evidence base on support options for individuals awaiting mental health care. Most notably, this study focuses on young people, a high-priority and under-researched population.

An additional key strength is its large sample size and real-world setting, drawing from across 11 CAMHS sites. The use of validated measures, Link Worker records and adjustment for several potential confounding variables also strengthened the study, although unmeasured differences between groups may still have influenced the findings.

Another strength was the involvement of a Youth Advisory Group in developing the intervention and selecting outcome measures, helping to ensure the study reflected young people’s priorities.

Limitations

Likewise, there are key limitations that should be considered:

  1. Non-randomisation: Given the staged rollout of social prescribing across CAMHS sites, participants were not randomly allocated to groups. Recruiting groups at different times could have introduced temporal confounding, such as seasonal effects or changes in service provision. Despite adjusting for several factors, unmeasured differences between groups may still have influenced the findings.
  2. Differences in uptake: Young people allocated to social prescribing who did not receive it were more likely to be male, from minority ethnic backgrounds and from socioeconomically disadvantaged backgrounds. This raises questions about potential barriers to accessing social prescribing. As these participants were excluded from the effectiveness analysis, the findings may not fully reflect the experiences of young people facing these barriers, or the effectiveness of offering social prescribing in routine practice.
  3. Differences in delivery: Social prescribing was delivered both in person and remotely, which may have influenced engagement and outcomes. It remains unclear which approaches were most effective.
  4. Exclusion criteria: Young people presenting with psychosis, eating disorders or severe and complex mental health difficulties were excluded, limiting the generalisability of findings to those with more complex needs.
  5. Missing data and follow-up: Of the 558 young people recruited, 449 were included in the effectiveness analysis, following exclusions due to intervention non-uptake and missing baseline data. This may have introduced selection bias. The six-month follow-up also means that the longer-term benefits of social prescribing remain unclear.
Five dice on a wooden table
The large, real-world sample strengthens the study, but non-randomisation and differences in uptake limit what we can conclude.

Implications for practice

It may be tempting to consider the findings of this study as evidence that social prescribing can be used as a substitute for symptom-focused clinical therapies. However, the scope of the study is limited to examining social prescribing as a potential supplement to CAMHS waiting list support. While social prescribing was associated with improvements in behavioural difficulties, prosocial behaviour and resilience, there were no significant differences in anxiety, depression or perceived stress. Therefore, social prescribing may offer additional support while young people wait, rather than replacing evidence-based psychological treatment.

Clinicians and mental health professionals should consider this study’s emphasis on community as a potential source of support. Previous research has also highlighted the potential role of community-based activities in supporting young people’s emotional and social development, although evidence on the effectiveness of social prescribing pathways remains limited (Mitchell et al., 2025). Connecting young people to community-based activities and resources may help strengthen their resilience and day-to-day functioning. However, the findings also highlight the importance of considering individual needs and preferences, as social prescribing may not be appropriate or accessible for everyone.

Importantly, young people who were allocated to social prescribing but did not receive it were more likely to be male, from minority ethnic backgrounds and from socioeconomically disadvantaged backgrounds. This raises questions about the structural barriers that may limit access to social prescribing, including the availability and affordability of community activities. Policymakers and service providers should therefore consider how funding, transport and local service provision may influence young people’s opportunities to engage.

Investment in community-based Link Workers and flexible delivery options, including remote support, could help address some of these barriers, although further research is needed to establish which approaches are most accessible and effective. Services would also need appropriate safeguarding arrangements, supervision and clear pathways to specialist care.

Finally, longer-term research is needed to examine whether the improvements observed in this study are sustained over time. Future studies should also explore whether social prescribing can be delivered equitably across different communities, and whether it offers meaningful benefits for young people who face the greatest barriers to accessing mental health support.

Ultimately, while social prescribing may help bridge gaps in support, it should not distract from the need to reduce CAMHS waiting times and ensure timely access to specialist mental health care.

A glass full of coins, with two green leaf shoots
Social prescribing may help bridge gaps in support, but equitable access and continued investment in specialist mental health services remain essential.

Statement of interest

Jocelyn Zacarias has no conflicting interest to declare. The blog was independently drafted by the author with the assistance of AI tools for language refinement only.

Edited by

Dr Nina Higson-Sweeney. ChatGPT was used for language refinement during the editorial phase.

Links

Primary paper

Daniel Hayes, Joely Wright, Alexandra Burton, Feifei Bu, Lou Sticpewich, Het Stuttard, Joanna Page, Alexandra Bradbury, Emeline Han, Jessica Deighton, Marc S. Tibber, Shivangi Talwar, & Daisy Fancourt (2026). Wellbeing while waiting: Effectiveness and implementation of youth social prescribing for young people awaiting CAMHS support. European Child & Adolescent Psychiatry, 1-12. https://doi.org/10.1007/s00787-026-03074-8 

Other references

Han, E., Burton, A., Bradbury, A., Hayes, D., Wright, J., Sticpewich, L., … & Fancourt, D. (2026). Experiences of youth and caregivers waiting for mental health services in the UK: a qualitative study to inform policy and practice. European Child & Adolescent Psychiatry, 1-11. https://doi.org/10.1007/s00787-025-02952-x

Kupcova, I., Danisovic, L., Klein, M., & Harsanyi, S. (2023). Effects of the COVID-19 pandemic on mental health, anxiety, and depression. BMC Psychology, 11, Article 108. https://doi.org/10.1186/s40359-023-01130-5

Mak, K. (2025). From pills to people: the rise of social prescribing. The Mental Elf.

Mitchell, S. B., Cartwright, L., Gude, A., Bethel, A., Hunt, H., Smith, J. R., Hayes, D., Bertotti, M., Jarvis-Beesley, P., Berry, V., & Husk, K. (2025). The use of social prescribing and community-based wellbeing activities as a potential prevention and early intervention pathway to improve adolescent emotional and social development: A systematic mapping review. BMC Public Health, 25, Article 3495. https://doi.org/10.1186/s12889-025-24413-5

Muhl, C., Cornish, E., Zhou, X. A., et al. (2025). Social prescribing for children and youth: A scoping review. Health & Social Care in the Community, 2025, Article 5265529. https://doi.org/10.1155/hsc/5265529

Photo credits

Continue reading

Resveratrol and Alzheimer’s: What a Randomized Trial Actually Found

Resveratrol, a compound found in red wine and grapes, became one of the most hyped anti-aging supplements of the last two decades, partly on the strength of laboratory research into longevity genes called sirtuins. In 2015, a 52-week randomized,...

India's Supplement Market to Nearly Double: Is Wellness Driving the Boom?

India's health supplements market could reach (Dollar) 9.4 billion by FY31. Explore how wellness trends, digital brands and quick commerce are reshaping supplement sales.

Why Bipolar Episodes Return — Even With Treatment

Even with treatment and stability, bipolar episodes can come back. Here’s how to spot the signs and strengthen your prevention plan. Key Takeaways Bipolar...